COZAAR COMP

Main information

  • Trade name:
  • COZAAR COMP
  • Dosage:
  • 100/12.5 Milligram
  • Pharmaceutical form:
  • Film Coated Tablet
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • COZAAR COMP
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PPA1659/016/001
  • Authorization date:
  • 08-10-2010
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

CozaarComp100mg/12.5mgfilm-coatedtablets

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains100mgoflosartanpotassiumand12.5mgofhydrochlorothiazide(HCTZ).

CozaarComp100mg/12.5mg:eachtabletcontains88.40mglactosemonohydrate.

Forafulllistofexcipients,seesection6.1.

3PHARMACEUTICALFORM

Filmcoatedtablet

ProductimportedfromtheUK:

White,ovalfilm-coatedtabletsmarked'745'ononesideandplainontheother.

4CLINICALPARTICULARS

4.1TherapeuticIndications

CozaarCompisindicatedfortreatmentofessentialhypertensioninpatientswhosebloodpressureisnotadequately

controlledonlosartanorhydrochlorothiazidealone.

4.2Posologyandmethodofadministration

CozaarCompmaybeadministeredwithotherantihypertensiveagents.

CozaarComptabletsshouldbeswallowedwithaglassofwater

CozaarCompmaybeadministeredwithorwithoutfood.

Hypertension

Losartanandhydrochlorothiazideisnotforuseasinitialtherapy,butinpatientswhosebloodpressureisnotadequately

controlledbylosartanpotassiumorhydrochlorothiazidealone.

Dosetitrationwiththeindividualcomponents(losartanandhydrochlorothiazide)isrecommended.

Whenclinicallyappropriatedirectchangefrommonotherapytothefixedcombinationmaybeconsideredinpatients

whosebloodpressureisnotadequatelycontrolled.

usual maintenance dose of Cozaar Comp is one tablet of Cozaar Comp50mg/12.5mg

(losartan50mg/HCTZ12.5mg) once daily. For patients who do not respond adequately to Cozaar

Comp50mg/12.5mg,thedosagemaybeincreasedtoonetabletofCozaarComp100mg/25mg(losartan100mg/

HCTZ25mg)oncedaily.ThemaximumdoseisonetabletofCozaarComp100mg/25mgoncedaily.Ingeneral,

theantihypertensiveeffectisattainedwithinthreetofourweeksafterinitiationoftherapy.CozaarComp100/12.5

(losartan100mg/HCTZ12.5mg)isavailableforthosepatientstitratedto100mgofCozaarCompwhorequire

additionalbloodpressurecontrol.

Useinpatientswithrenalimpairmentandhaemodialysispatients

Noinitialdosageadjustmentisnecessaryinpatientswithmoderaterenalimpairment(i.e.creatinineclearance

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 1

Losartan/HCTZtabletsmustnotbeusedinpatientswithsevererenalimpairment(i.e.creatinineclearance<30ml/min)

(seesection4.3).

Useinpatientswithintravascularvolumedepletion

Volumeand/orsodiumdepletionshouldbecorrectedpriortoadministrationofLosartan/HCTZtablets.

Useinpatientswithhepaticimpairment

Losartan/HCTZiscontraindicatedinpatientswithseverehepaticimpairment(seesection4.3.).

Useintheelderly

Dosageadjustmentisnotusuallynecessaryfortheelderly.

Useinchildrenandadolescents(<18years)

Thereisnoexperienceinchildrenandadolescents.Therefore,losartan/hydrochlorothiazideshouldnotbeadministered

tochildrenandadolescents.

4.3Contraindications

Hypersensitivitytolosartan,sulphonamide-derivedsubstances(ashydrochlorothiazide)ortoanyoftheexcipients

Therapyresistanthypokalaemiaorhypercalcaemia

Severehepaticimpairment;cholestasisandbiliaryobstructivedisorders

Refractoryhyponatraemia

Symtomatichyperuricaemia/gout

2ndand3rdtrimesterofpregnancy(seesection4.4and4.6)

Severerenalimpairment(i.e.creatinineclearance<30ml/min)

Anuria

4.4Specialwarningsandprecautionsforuse

Losartan

Angiooedema

Patientswithahistoryofangiooedema(swellingoftheface,lips,throat,and/ortongue)shouldbecloselymonitored

(seesection4.8).

HypotensionandIntravascularvolumedepletion

Symptomatichypotension,especiallyafterthefirstdose,mayoccurinpatientswhoarevolume-and/orsodium-

depletedbyvigorousdiuretictherapy,dietarysaltrestriction,diarrhoeaorvomiting.Suchconditionsshouldbe

correctedbeforetheadministrationofCozaarComptablets(seesections4.2.and4.3.).

Electrolyteimbalances

Electrolyteimbalancesarecommoninpatientswithrenalimpairment,withorwithoutdiabetes,andshouldbe

addressed.Therefore,theplasmaconcentrationsofpotassiumandcreatinineclearancevaluesshouldbeclosely

monitored;especiallypatientswithheartfailureandacreatinineclearancebetween30-50ml/minshouldbeclosely

monitored.

Theconcomitantuseofpotassiumsparingdiuretics,potassiumsupplementsandpotassiumcontainingsaltsubstitutes

withlosartan/hydrochlorothiazideisnotrecommended(seesection4.5).

Liverfunctionimpairment

Basedonpharmacokineticdatawhichdemonstratesignificantlyincreasedplasmaconcentrationsoflosartanincirrhotic

patients,CozaarCompshouldbeusedwithcautioninpatientswithahistoryofmildtomoderatehepaticimpairment.

Thereisnotherapeuticexperiencewithlosartaninpatientswithseverehepaticimpairment.ThereforeCozaarCompis

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 2

Renalfunctionimpairment

Asaconsequenceofinhibitingtherenin-angiotensin-aldosteronesystem,changesinrenalfunction,includingrenal

failure,havebeenreported(inparticular,inpatientswhoserenalfunctionisdependentontherenin-angiotensin-

aldosteronesystem,suchasthosewithseverecardiacinsufficiencyorpre-existingrenaldysfunction).

Aswithotherdrugsthataffecttherenin-angiotensin-aldosteronesystem,increasesinbloodureaandserumcreatinine

havealsobeenreportedinpatientswithbilateralrenalarterystenosisorstenosisofthearterytoasolitarykidney;these

changesinrenalfunctionmaybereversibleupondiscontinuationoftherapy.Losartanshouldbeusedwithcautionin

patientswithbilateralrenalarterystenosisorstenosisofthearterytoasolitarykidney.

Renaltransplantation

Thereisnoexperienceinpatientswithrecentkidneytransplantation.

Primaryhyperaldosteronism

Patientswithprimaryaldosteronismgenerallywillnotrespondtoantihypertensivedrugsactingthroughinhibitionof

therenin-angiotensinsystem.Therefore,theuseofCozaarComptabletsisnotrecommended.

Coronaryheartdiseaseandcerebrovasculardisease:

Aswithanyantihypertensiveagents,excessivebloodpressuredecreaseinpatientswithischaemiccardiovascularand

cerebrovasculardiseasecouldresultinamyocardialinfarctionorstroke.

Heartfailure:

Inpatientswithheartfailure,withorwithoutrenalimpairment,thereis-aswithotherdrugsactingontherenin-

angiotensinsystem-ariskofseverearterialhypotension,and(oftenacute)renalimpairment.

Aorticandmitralvalvestenosis,obstructivehypertrophiccardiomyophathy

Aswithothervasodilators,specialcautionisindicatedinpatientssufferingfromaorticormitralstenosis,orobstructive

hypertrophiccardiomyopathy.

Ethnicdifferences

Asobservedforangiotensinconvertingenzymeinhibitors,losartanandtheotherangiotensinantagonistsareapparently

lesseffectiveinloweringbloodpressureinblackpeoplethaninnon-blacks,possiblybecauseofhigherprevalenceof

low-reninstatesintheblackhypertensivepopulation.

Pregnancy

AIIRAsshouldnotbeinitiatedduringpregnancy.UnlesscontinuedAIIRAtherapyisconsideredessential,patients

planningpregnancyshouldbechangedtoalternativeanti-hypertensivetreatmentswhichhaveanestablishedsafety

profileforuseinpregnancy.Whenpregnancyisdiagnosed,treatmentwithAIIRAsshouldbestoppedimmediately,

and,ifappropriate,alternativetherapyshouldbestarted(seesections4.3and4.6).

Hydrochlorothiazide

Hypotensionandelectrolyte/fluidimbalance

Aswithallantihypertensivetherapy,symptomatichypotensionmayoccurinsomepatients.Patientsshouldbe

observedforclinicalsignsoffluidorelectrolyteimbalance,e.g.,volumedepletion,hyponatremia,hypochloremic

alkalosis,hypomagnesemiaorhypokalemiawhichmayoccurduringintercurrentdiarrheaorvomiting.Periodic

determinationofserumelectrolytesshouldbeperformedatappropriateintervalsinsuchpatients.Dilutional

hyponatraemiamayoccurinoedematouspatientsinhotweather.

Metabolicandendocrineeffects

Thiazidetherapymayimpairglucosetolerance.Dosageadjustmentofantidiabeticagents,includinginsulin,maybe

required(seesection4.5).Latentdiabetesmellitusmaybecomemanifestduringthiazidetherapy.

Thiazidesmaydecreaseurinarycalciumexcretionandmaycauseintermittentandslightelevationofserumcalcium.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 3

Thiazidesshouldbediscontinuedbeforecarryingouttestsforparathyroidfunction.

Increasesincholesterolandtriglyceridelevelsmaybeassociatedwiththiazidediuretictherapy.

Thiazidetherapymayprecipitatehyperuricemiaand/orgoutincertainpatients.Becauselosartandecreasesuricacid,

losartanincombinationwithhydrochlorothiazideattenuatesthediuretic-inducedhyperuricemia.

Hepaticimpairment

Thiazidesshouldbeusedwithcautioninpatientswithimpairedhepaticfunctionorprogressiveliverdisease,asitmay

causeintrahepaticcholestasis,andsinceminoralterationsoffluidandelectrolytebalancemayprecipitatehepatic

coma.

CozaarCompiscontraindicatedforpatientswithseverehepaticimpairment(seesection4.3and5.2).

Other

Inpatientsreceivingthiazides,hypersensitivityreactionsmayoccurwithorwithoutahistoryofallergyorbronchial

asthma.Exacerbationoractivationofsystemiclupuserythematosushasbeenreportedwiththeuseofthiazides.

Excipient

Thismedicinalproductcontainslactose.Patientswithrarehereditaryproblemsofgalactoseintolerance,theLapp

lactasedeficiencyorglucose-galactosemalabsorptionshouldnottakethismedicine.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Losartan

Rifampicinandfluconazolehavebeenreportedtoreducelevelsofactivemetabolite.Theclinicalconsequencesof

theseinteractionshavenotbeenevaluated.

AswithotherdrugsthatblockangiotensinIIoritseffects,concomitantuseofpotassium-sparingdiuretics(e.g.,

spironolactone,triamterene,amiloride),potassiumsupplements,orsaltsubstitutescontainingpotassiummayleadto

increasesinserumpotassium.Co-medicationisnotadvisable.

Aswithothermedicineswhichaffecttheexcretionofsodium,lithiumexcretionmaybereduced.Therefore,serum

lithiumlevelsshouldbemonitoredcarefullyiflithiumsaltsaretobeco-administeredwithangiotensinIIreceptor

antagonists.

WhenangiotensinIIantagonistsareadministeredsimultaneouslywithNSAIDs(i.e.selectiveCOX-2inhibitors,

acetylsalicylicacidatanti-inflammatorydoses)andnon-selectiveNSAIDs,attenuationoftheantihypertensiveeffect

mayoccur.ConcomitantuseofangiotensinIIantagonistsordiureticsandNSAIDsmayleadtoanincreasedriskof

worseningofrenalfunction,includingpossibleacuterenalfailure,andanincreaseinserumpotassium,especiallyin

patientswithpoorpre-existingrenalfunction.Thecombinationshouldbeadministeredwithcaution,especiallyinthe

elderly.Patientsshouldbeadequatelyhydratedandconsiderationshouldbegiventomonitoringrenalfunctionafter

initiationofconcomitanttherapy,andperiodicallythereafter.

Insomepatientswithcompromisedrenalfunctionwhoarebeingtreatedwithnon-steroidalanti-inflammatorydrugs,

includingselectivecyclooxygenase-2inhibitors,theco-administrationofangiotensinIIreceptorantagonistsmayresult

inafurtherdeteriorationofrenalfunction.Theseeffectsareusuallyreversible.

Othersubstancesinducinghypotensionliketricyclicantidepressants,antipsychotics,baclofene,amifostine:

Concomitantusewiththesedrugsthatlowerbloodpressure,asmainorside-effect,mayincreasetheriskof

hypotension.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 4

Whengivenconcurrently,thefollowingdrugsmayinteractwiththiazidediuretics:

Alcohol,barbiturates,narcoticsorantidepressants:

Potentiationoforthostatichypotensionmayoccur.

Antidiabeticdrugs(oralagentsandinsulin):

Thetreatmentwithathiazidemayinfluencetheglucosetolerance.Dosageadjustmentoftheantidiabeticdrugmaybe

required.Metforminshouldbeusedwithcautionbecauseoftheriskoflacticacidosisinducedbypossiblefunctional

renalfailurelinkedtohydrochlorothiazide.

Otherantihypertensivedrugs

Additiveeffect.

Cholestyramineandcolestipolresins:

Absorptionofhydrochlorothiazideisimpairedinthepresenceofanionicexchangeresins.Singledosesofeither

cholestyramineorcolestipolresinsbindthehydrochlorothiazideandreduceitsabsorptionfromthegastrointestinal

tractbyupto85and43percent,respectively.

Corticosteroids,ACTH

Intensifiedelectrolytedepletion,particularlyhypokalemia.

Pressoramines(e.g.,adrenaline)

Possibledecreasedresponsetopressoraminesbutnotsufficienttoprecludetheiruse.

Skeletalmusclerelaxants,nondepolarizing(e.g.,tubocurarine)

Possibleincreasedresponsivenesstothemusclerelaxant.

Lithium

Diureticagentsreducetherenalclearanceoflithiumandaddahighriskoflithiumtoxicity;concomitantuseisnot

recommended.

Medicinalproductsusedinthetreatmentofgout(probenecid,sulfinpyrazoneandallopurinol)

Dosageadjustmentofuricosuricmedicinalproductsmaybenecessarysincehydrochlorothiazidemayraisethelevelof

serumuricacid.Increaseindosageofprobenecidorsulfinpyrazonemaybenecessary.Coadministrationofathiazide

mayincreasetheincidenceofhypersensitivityreactionstoallopurinol.

Anticholinergicagents(e.g.atropine,biperiden)

Increaseofthebioavailabilitytothiazide-typediureticsbydecreasinggastrointestinalmotilityandstomachemptying

rate.

Cytotoxicagents(egcyclophosphamide,methotrexate)

Thiazidesmayreducetherenalexcretionofcytotoxicmedicinalproductsandpotentiatetheirmyelosuppressiveeffects.

Salicylates

Incaseofhighdosagesofsalicylateshydrochlorothiazidemayenhancethetoxiceffectofthesalicylatesonthecentral

nervoussystem.

Methyldopa

Therehavebeenisolatedreportsofhaemolyticanaemiaoccurringwithconcomitantuseofhydrochlorothiazideand

methyldopa.

Cyclosporine

Concomitanttreatmentwithcyclosporinemayincreasetheriskofhyperuricaemiaandgout-typecomplications.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 5

Thiazide-inducedhypokalaemiaorhypomagnesaemiamayfavourtheonsetofdigitalis-inducedcardiacarrhythmias.

Medicinalproductsaffectedbyserumpotassiumdisturbances

PeriodicmonitoringofserumpotassiumandECGisrecommendedwhenlosartan/hydrochlorothiazideisadministered

withmedicinalproductsaffectedbyserumpotassiumdisturbances(e.g.digitalisglycosidesandantiarrhythmics)and

withthefollowingtorsadesdepointes(ventriculartachycardia)-inducingmedicinalproducts(includingsome

antiarrhythmics),hypokalaemiabeingapredisposingfactortotorsadesdepointes(ventriculartachycardia):

ClassIaantiarrythmics(egquinidine,hydroquinidine,disopyramide).

ClassIIIantiarrythmics(egamiodarone,sotalol,dofetilide,ibutilide).

Someantipsychotics(egthioridazine,chlorpromazine,levomepromazine,trifluoperazine,cyamemazine,sulpiride,

sultopride,amisulpride,tiapride,pimozide,haloperidol,droperidol).

Others(egbepridil,cisapride,diphemanil,erythromycinIV,halofantrin,mizolastin,pentamidine,terfenadine,

vincamineIV).

Calciumsalts

Thiazidediureticsmayincreaseserumcalciumlevelsduetodecreasedexcretion.Ifcalciumsupplementsmustbe

prescribed,serumcalciumlevelsshouldbemonitoredandcalciumdosageshouldbeadjustedaccordingly.

LaboratoryTestInteractions

Becauseoftheireffectsoncalciummetabolism,thiazidesmayinterferewithtestsforparathyroidfunction(seesection

4.4).

Carbamazepine

Riskofsymptomatichyponatremia.Clinicalandbiologicalmonitoringisrequired.

IodineContrastMedia

Incaseofdiuretic-induceddehydration,thereisanincreasedriskofacuterenalfailure,especiallywithhighdosesof

theiodineproduct.Patientsshouldberehydratedbeforetheadministration.

AmphotericinB(parenteral),corticosteroids,ACTHorstimulantlaxatives

Hydrochlorothiazidemayintensifyelectrolyteimbalance,particularlyhypokalaemia.

4.6Pregnancyandlactation

Pregnancy

TheuseofAIIRAsisnotrecommendedduringthefirsttrimesterofpregnancy(seesection4.4).TheuseofAIIRAsis

contra-indicatedduringthe2ndand3rdtrimesterofpregnancy(seesection4.3and4.4).

EpidemiologicalevidenceregardingtheriskofteratogenicityfollowingexposuretoACEinhibitorsduringthefirst

trimesterofpregnancyhasnotbeenconclusive;howeverasmallincreaseinriskcannotbeexcluded.Whilstthereisno

controlledepidemiologicaldataontheriskwithAngiotensinIIReceptorInhibitors(AIIRAs),similarrisksmayexist

forthisclassofdrugs.UnlesscontinuedAIIRAtherapyisconsideredessential,patientsplanningpregnancyshouldbe

changedtoalternativeanti-hypertensivetreatmentswhichhaveanestablishedsafetyprofileforuseinpregnancy.

Whenpregnancyisdiagnosed,treatmentwithAIIRAsshouldbestoppedimmediatelyand,ifappropriate,alternative

therapyshouldbestarted.

ExposuretoAIIRAtherapyduringthesecondandthirdtrimestersisknowntoinducehumanfetotoxicity(decreased

renalfunction,oligohydramnios,skullossificationretardation)andneonataltoxicity(renalfailure,hypotension,

hyperkalaemia)(seesection5.3).

ShouldexposuretoAIIRAshaveoccurredfromthesecondtrimesterofpregnancy,ultrasoundcheckofrenalfunction

andskullisrecommended.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 6

Thereislimitedexperiencewithhydrochlorothiazideduringpregnancy,especiallyduringthefirsttrimester.Animal

studiesareinsufficient.

Hydrochlorothiazidecrossestheplacenta.Basedonthepharmacologicalmechanismofactionofhydrochlorothiazide,

itsuseduringsecondandthirdtrimestersmaycompromisefoeto-placentalperfusionandmaycausefoetalandneonatal

effectslikeicterus,disturbanceofelectrolytebalanceandthrombocytopenia.

Hydrochlorothiazideshouldnotbeusedforgestationaloedema,gestationalhypertensionorpreeclampsiaduetothe

riskofdecreasedplasmavolumeandplacentalhypoperfusion,withoutabeneficialeffectonthecourseofthedisease.

Hydrochlorothiazideshouldnotbeusedforessentialhypertensioninpregnantwomen,exceptinraresituationswhere

nootheralternativetreatmentcouldbeused.

Lactation

NoinformationisavailableregardingtheuseofCozaarCompduringbreastfeeding.Hydrochlorothiazideisexcretedin

humanmilk.Therefore,theuseofCozaarCompduringbreastfeedingisnotrecommended.Alternativetreatmentswith

betterestablishedsafetyprofilesduringbreastfeedingarepreferable,especiallywhilenursinganewbornorpreterm

infant.

4.7Effectsonabilitytodriveandusemachines

Nostudiesonthereactionsontheabilitytodriveandusemachineshavebeenperformed.However,whendriving

vehiclesoroperatingmachineryitmustbeborneinmindthatdizzinessordrowsinessmayoccasionallyoccurwhen

takingantihypertensivetherapy,inparticularduringinitiationoftreatmentorwhenthedoseisincreased.

4.8Undesirableeffects

Theadversereactionsbelowareclassifiedwhereappropriatebysystemorganclassandfrequencyaccordingtothe

followingconvention:

Verycommon: ≥1/10

Common: ≥1/100,<1/10

Uncommon: ≥1/1,000,≤1/100

Rare: ≥1/10,000,≤1/1,000

Veryrare: ≤1/10,000

Notknown: ≤1/10,000

(cannotbeestimatedfromtheavailabledata)

Inclinicaltrialswithlosartanpotassiumsaltandhydrochlorothiazide,noadversereactionspeculiartothiscombination

ofsubstanceswereobserved.Theadversereactionswererestrictedtothosewhichwereformerlyobservedwith

losartanpotassiumsaltand/orhydrochlorothiazide.

Incontrolledclinicaltrialsforessentialhypertension,dizzinesswastheonlyadversereactionreportedassubstance-

relatedthatoccurredwithanincidencegreaterthanplaceboin1%ormoreofpatientstreatedwithlosartanand

hydrochlorothiazide.

Nexttotheseeffects,therearefurtheradversereactionsreportedaftertheintroductionoftheproducttothemarketas

follows:

Hepato-biliarydisorders

rare:Hepatitis

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 7

rare:Hyperkalaemia,elevationofALT

Additionaladversereactionsthathavebeenseenwithoneoftheindividualcomponentsandmaybepotentialadverse

reactionswithlosartanpotassium/hydrochlorothiazidearethefollowing:

Losartan

Bloodandlymphaticsystemdisorders

uncommon: Anaemia,Henoch-Schönleinpurpura,ecchymosis,haemolysis

Immunesystemdisorders

rare: Anaphylacticreactions,angioedema,urticaria

Metabolismandnutritiondisorders

uncommon: Anorexia,gout

Psychiatricdisorders

common: Insomnia

uncommon: Anxiety,anxietydisorder,panicdisorder,confusion,depression,abnormaldreams,sleepdisorder,

somnolence,memoryimpairment

Nervoussystemdisorders

common: Headache,dizziness

uncommon: Nervousness,paraesthesia,peripheralneuropathy,tremor,migraine,syncope

Eyedisorders

uncommon: Blurredvision,burning/stingingintheeye,conjunctivitis,decreaseinvisualacuity

Earandlabyrinthdisorders

uncommon: Vertigo,tinnitus

Cardiacdisorders

uncommon: Hypotension,orthostatichypotension,sternalgia,anginapectoris,gradeII-AVblock,cerebrovascular

event,myocardialinfarction,palpitation,arrhythmias(atrialfibrillations,sinusbradycardia,tachycardia,ventricular

tachycardia,ventricularfibrillation)

Vasculardisorders

uncommon: Vasculitis

Respiratory,thoracicandmediastinaldisorders

common: Cough,upperrespiratoryinfection,nasalcongestion,sinusitis,sinusdisorder

uncommon: Pharyngealdiscomfort,pharyngitis,laryngitis,dyspnoea,bronchitis,epistaxis,rhinitis,respiratory

congestion

Gastrointestinaldisorders

common: Abdominalpain,nausea,diarrhoea,dyspepsia

uncommon: Constipation,dentalpain,drymouth,flatulence,gastritis,vomiting

Hepato-biliarydisorders

notknown: Liverfunctionabnormalities

Skinandsubcutaneoustissuedisorders

uncommon: Alopecia,dermatitis,dryskin,erythema,flushing,photosensitivity,pruritus,rash,urticaria,sweating

Musculoskeletalandconnectivetissuedisorders

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 8

uncommon: Armpain,jointswelling,kneepain,musculoskeletalpain,shoulderpain,stiffness,arthralgia,arthritis,

coxalgia,fibromyalgia,muscleweakness

Renalandurinarydisorders

uncommon: Nocturia,urinaryfrequency,urinarytractinfection

Reproductivesystemandbreastdisorders

uncommon: Decreasedlibido,impotence

Generaldisordersandadministrationsiteconditions

common: Asthenia,fatigue,chestpain

uncommon: Facialoedema,fever

Investigations

common: Hyperkalaemia,mildreductionofhaematocritandhaemoglobin

uncommon: Mildincreaseinureaandcreatinineserumlevels

veryrare: Increaseinhepaticenzymesandbilirubin.

Hydrochlorothiazide

Bloodandlymphaticsystemdisorders

uncommon: Agranulocytosis,aplasticanaemia,haemolyticanaemia,leukopenia,purpura,thrombocytopenia

Immunesystemdisorders

rare: Anaphylacticreaction

Metabolismandnutritiondisorders

uncommon: Anorexia,hyperglycaemia,hyperuricaemia,hypokalaemia,hyponatraemia

Psychiatricdisorders

uncommon: Insomnia

Nervoussystemdisorders

common: Cephalalgia

Eyedisorders

uncommon: Transientblurredvision,xanthopsia

Vasculardisorders

uncommon: Necrotizingangiitis(vasculitis,cutaneousvasculitis)

Respiratory,thoracicandmediastinaldisorders

uncommon: Respiratorydistressincludingpneumonitisandpulmonaryoedema

Gastrointestinaldisorders

uncommon: Sialoadenitis,spasms,stomachirritation,nausea,vomiting,diarrhoea,constipation

Hepato-biliarydisorders

uncommon: Icterus(intrahepaticcholestatis),pancreatitis

Skinandsubcutaneoustissuedisorders

uncommon: Photosensitivity,urticaria,toxicepidermalnecrolysis

Musculoskeletalandconnectivetissuedisorders

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 9

Renalandurinarydisorders

uncommon: Glycosuria,interstitialnephritis,renaldysfunction,renalfailure

Generaldisordersandadministrationsiteconditions

uncommon: Fever,dizziness

4.9Overdose

NospecificinformationisavailableonthetreatmentofoverdosagewithCozaarComp.

Treatmentissymptomaticandsupportive.TherapywithCozaarCompshouldbediscontinuedandthepatientobserved

closely.Suggestedmeasuresincludeinductionofemesisifingestionisrecent,andcorrectionofdehydration,

electrolyteimbalance,hepaticcomaandhypotensionbyestablishedprocedures.

Losartan

Limiteddataareavailableinregardtooverdosageinhumans.Themostlikelymanifestationofoverdosagewouldbe

hypotensionandtachycardia;bradycardiacouldoccurfromparasympathetic(vagal)stimulation.Ifsymptomatic

hypotensionshouldoccur,supportivetreatmentshouldbeinstituted.

Neitherlosartannortheactivemetabolitecanberemovedbyhemodialysis.

Hydrochlorothiazide

Themostcommonsignsandsymptomsobservedarethosecausedbyelectrolytedepletion(hypokalemia,

hypochloremia,hyponatremia)anddehydrationresultingfromexcessivediuresis.Ifdigitalishasalsobeen

administered,hypokalemiamayaccentuatecardiacarrhythmias.

Thedegreetowhichhydrochlorothiazideisremovedbyhemodialysishasnotbeenestablished.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Pharmacotherapeuticgroup:AngiotensinIIantagonistsanddiuretics,

ATCcode:C09DA01

Losartan-Hydrochlorothiazide

ThecomponentsofCozaarComphavebeenshowntohaveanadditiveeffectonbloodpressurereduction,reducing

bloodpressuretoagreaterdegreethaneithercomponentalone.Thiseffectisthoughttobearesultofthe

complimentaryactionsofbothcomponents.Further,asaresultofitsdiureticeffect,hydrochlorothiazideincreases

plasmareninactivity,increasesaldosteronesecretion,decreasesserumpotassium,andincreasesthelevelsof

angiotensinII.AdministrationoflosartanblocksallthephysiologicallyrelevantactionsofangiotensinIIandthrough

inhibitionofaldosteronecouldtendtoattenuatethepotassiumlossassociatedwiththediuretic.

Losartanhasbeenshowntohaveamildandtransienturicosuriceffect.Hydrochlorothiazidehasbeenshowntocause

modestincreasesinuricacid;thecombinationoflosartanandhydrochlorothiazidetendstoattenuatethediuretic-

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 10

TheantihypertensiveeffectofCozaarCompissustainedfora24-hourperiod.Inclinicalstudiesofatleastoneyear's

duration,theantihypertensiveeffectwasmaintainedwithcontinuedtherapy.Despitethesignificantdecreaseinblood

pressure,administrationofCozaarComphadnoclinicallysignificanteffectonheartrate.Inclinicaltrials,after12

weeksoftherapywithlosartan50mg/hydrochlorothiazide12.5mg,troughsittingdiastolicbloodpressurewasreduced

byanaverageofupto13.2mmHg.

CozaarCompiseffectiveinreducingbloodpressureinmalesandfemales,blacksandnon-blacksandinyounger(<65

years)andolder( ≥65years)patientsandiseffectiveinalldegreesofhypertension.

Losartan

Losartanisasyntheticallyproducedoralangiotensin-IIreceptor(typeAT

)antagonist.AngiotensinII,apotent

vasoconstrictor,istheprimaryactivehormonoftherenin-angiotensinsystemandanimportantdeterminantofthe

pathophysiologyofhypertension.AngiotensinIIbindstotheAT

receptorfoundinmanytissues(e.g.vascularsmooth

muscle,adrenalgland,kidneysandtheheart)andelicitsseveralimportantbiologicalactions,including

vasoconstrictionandthereleaseofaldosterone.AngiotensinIIalsostimulatessmooth-musclecellproliferation.

LosartanselectivelyblockstheAT

receptor.Invitroandinvivolosartananditspharmacologicallyactivecarboxylic

acidmetaboliteE-3174blockallphysiologicallyrelevantactionsofangiotensinII,regardlessofthesourceorrouteof

itssynthesis.

Losartandoesnothaveanagonisteffectnordoesitblockotherhormonereceptorsorionchannelsimportantin

cardiovascularregulation.Furthermore,losartandoesnotinhibitACE(kininaseII),theenzymethatdegrades

bradykinin.Consequently,thereisthusnoincreaseinbradykinin-mediatedundesirableeffects.

DuringtheadministrationoflosartantheremovaloftheangiotensinIInegativefeedbackonreninsecretionleadsto

increasedplasma-reninactivity(PRA).IncreaseinthePRAleadstoanincreaseinangiotensinIIinplasma.Despite

theseincreases,antihypertensiveactivityandsuppressionoftheplasmaaldosteroneconcentrationaremaintained,

indicatingeffectiveangiotensinIIreceptorblockade.Afterthediscontinuationoflosartan,PRAandangiotensinII

valuesfellwithin3daystothebaselinevalues.

BothlosartananditsprincipalactivemetabolitehaveafargreateraffinityfortheAT

receptorthanfortheAT

receptor.Theactivemetaboliteis10-to40-timesmoreactivethanlosartanonaweightforweightbasis.

Inastudyspecificallydesignedtoassesstheincidenceofcoughinpatientstreatedwithlosartanascomparedto

patientstreatedwithACEinhibitors,theincidenceofcoughreportedbypatientsreceivinglosartanor

hydrochlorothiazidewassimilarandwassignificantlylessthaninpatientstreatedwithanACEinhibitor.Inaddition,

inanoverallanalysisof16double-blindclinicaltrialsin4131patients,theincidenceofspontaneouslyreportedcough

inpatientstreatedwithlosartanwassimilar(3.1%)tothatofpatientstreatedwithplacebo(2.6%)or

hydrochlorothiazide(4.1%),whereastheincidencewithACEinhibitorswas8.8%.

Innondiabetichypertensivepatientswithproteinuria,theadministrationoflosartanpotassiumsignificantlyreduces

proteinuria,fractionalexcretionofalbuminandIgG.Losartanmaintainsglomerularfiltrationrateandreducesfiltration

fraction.Generallylosartancausesadecreaseinserumuricacid(usually<0.4mg/dL)whichwaspersistentinchronic

therapy.

Losartanhasnoeffectonautonomicreflexesandnosustainedeffectonplasmanorepinephrine.

Inpatientswithleftventricularfailure,25mgand50mgdosesoflosartanproducedpositivehemodynamicand

neurohormonaleffectscharacterizedbyanincreaseincardiacindexanddecreasesinpulmonarycapillarywedge

pressure,systemicvascularresistance,meansystemicarterialpressureandheartrateandareductionincirculating

levelsofaldosteroneandnorepinephrine,respectively.Theoccurrenceofhypotensionwasdoserelatedintheseheart

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 11

HypertensionStudies

Incontrolledclinicalstudies,once-dailyadministrationoflosartantopatientswithmildtomoderateessential

hypertensionproducedstatisticallysignificantreductionsinsystolicanddiastolicbloodpressure.Measurementof

bloodpressure24hourspost-doserelativeto5–6hourspost-dosedemonstratedbloodpressurereductionover24

hours;thenaturaldiurnalrhythmwasretained.Bloodpressurereductionattheendofthedosingintervalwas70–80

%oftheeffectseen5-6hourspost-dose.

Discontinuationoflosartaninhypertensivepatientsdidnotresultinanabruptriseinbloodpressure(rebound).Despite

themarkeddecreaseinbloodpressure,losartanhadnoclinicallysignificanteffectonheartrate.

Losartanisequallyeffectiveinmalesandfemales,andinyounger(belowtheageof65years)andolderhypertensive

patients.

LIFEStudy

TheLosartanInterventionForEndpointreductioninhypertension(LIFE)studywasarandomised,triple-blind,active-

controlledstudyin9193hypertensivepatientsaged55to80yearswithECG-documentedleftventricularhypertrophy.

Patientswererandomisedtooncedailylosartan50mgoroncedailyatenolol50mg.Ifgoalbloodpressure

(<140/90mmHg)wasnotreached,hydrochlorothiazide(12.5mg)wasaddedfirstand,ifneeded,thedoseoflosartan

oratenololwasthenincreasedto100mgoncedaily.Otherantihypertensives,withtheexceptionofACEinhibitors,

angiotensinIIantagonistsorbeta-blockerswereaddedifnecessarytoreachthegoalbloodpressure.

Themeanlengthoffollowupwas4.8years.

Theprimaryendpointwasthecompositeofcardiovascularmorbidityandmortalityasmeasuredbyareductioninthe

combinedincidenceofcardiovasculardeath,strokeandmyocardialinfarction.Bloodpressurewassignificantly

loweredtosimilarlevelsinthetwogroups.Treatmentwithlosartanresultedina13.0%riskreduction(p=0.021,95%

confidenceinterval0.77-0.98)comparedwithatenololforpatientsreachingtheprimarycompositeendpoint.Thiswas

mainlyattributabletoareductionoftheincidenceofstroke.Treatmentwithlosartanreducedtheriskofstrokeby25%

relativetoatenolol(p=0.00195%confidenceinterval0.63-0.89).Theratesofcardiovasculardeathandmyocardial

infarctionwerenotsignificantlydifferentbetweenthetreatmentgroups.

Hydrochlorothiazide

Hydrochlorothiazideisathiazidediuretic.Themechanismoftheantihypertensiveeffectofthiazidediureticsisnot

fullyknown.Thiazidesaffecttherenaltubularmechanismsofelectrolytereabsorption,directlyincreasingexcretionof

sodiumandchlorideinapproximatelyequivalentamounts.Thediureticactionofhydrochlorothiazidereducesplasma

volume,increasesplasmareninactivityandincreasesaldosteronesecretion,withconsequentincreasesinurinary

potassiumandbicarbonateloss,anddecreasesinserumpotassium.Therenin-aldosteronelinkismediatedby

angiotensinIIandthereforecoadministrationofanangiotensinIIreceptorantagonisttendstoreversethepotassium

lossassociatedwiththiazidediuretics.

Afteroraluse,diuresisbeginswithin2hours,peaksinabout4hoursandlastsabout6to12hourstheantihypertensive

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 12

5.2Pharmacokineticproperties

Absorption

Losartan

Followingoraladministration,losartaniswellabsorbedandundergoesfirst-passmetabolism,forminganactive

carboxylicacidmetaboliteandotherinactivemetabolites.Thesystemicbioavailabilityoflosartantabletsis

approximately33%.Meanpeakconcentrationsoflosartananditsactivemetabolitearereachedin1hourandin3-4

hours,respectively.Therewasnoclinicallysignificanteffectontheplasmaconcentrationprofileoflosartanwhenthe

drugwasadministeredwithastandardizedmeal.

Distribution

Losartan

Bothlosartananditsactivemetaboliteare 99%boundtoplasmaproteins,primarilyalbumin.Thevolumeof

distributionoflosartanis34liters.Studiesinratsindicatethatlosartancrossestheblood-brainbarrierpoorly,ifatall.

Hydrochlorothiazide

Hydrochlorothiazidecrossestheplacentalbutnottheblood-brainbarrierandisexcretedinbreastmilk.

Biotransformation

Losartan

About14%ofanintravenously-ororally-administereddoseoflosartanisconvertedtoitsactivemetabolite.Following

oralandintravenousadministrationof C-labeledlosartanpotassium,circulatingplasmaradioactivityprimarilyis

attributedtolosartananditsactivemetabolite.Minimalconversionoflosartantoitsactivemetabolitewasseenin

aboutonepercentofindividualsstudied.

Inadditiontotheactivemetabolite,inactivemetabolitesareformed,includingtwomajormetabolitesformedby

hydroxylationofthebutylsidechainandaminormetabolite,anN-2tetrazoleglucuronide.

Elimination

Losartan

Plasmaclearanceoflosartananditsactivemetaboliteisabout600ml/minand50ml/min,respectively.Renalclearance

oflosartananditsactivemetaboliteisabout74ml/minand26ml/min,respectively.Whenlosartanisadministered

orally,about4%ofthedoseisexcretedunchangedintheurine,andabout6%ofthedoseisexcretedintheurineas

activemetabolite.Thepharmacokineticsoflosartananditsactivemetabolitearelinearwithorallosartanpotassium

dosesupto200mg.

Followingoraladministration,plasmaconcentrationsoflosartananditsactivemetabolitedeclinepolyexponentially

withaterminalhalf-lifeofabout2hoursand6-9hours,respectively.Duringonce-dailydosingwith100mg,neither

losartannoritsactivemetaboliteaccumulatessignificantlyinplasma.

Bothbiliaryandurinaryexcretioncontributetotheeliminationoflosartananditsmetabolites.Followinganoraldose

C-labeledlosartaninman,about35%ofradioactivityisrecoveredintheurineand58%inthefeces.

Hydrochlorothiazide

Hydrochlorothiazideisnotmetabolizedbutiseliminatedrapidlybythekidney.Whenplasmalevelshavebeen

followedforatleast24hours,theplasmahalf-lifehasbeenobservedtovarybetween5.6and14.8hours.Atleast61

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 13

CharacteristicsinPatients

Losartan-Hydrochlorothiazide

Theplasmaconcentrationsoflosartananditsactivemetaboliteandtheabsorptionofhydrochlorothiazideinelderly

hypertensivesarenotsignificantlydifferentfromthoseinyounghypertensives.

Losartan

Followingoraladministrationinpatientswithmildtomoderatealcoholiccirrhosisoftheliver,plasmaconcentrations

oflosartananditsactivemetabolitewere,respectively,5-foldand1.7-foldgreaterthanthoseseeninyoungmale

volunteers.

Neitherlosartannortheactivemetabolitecanberemovedbyhemodialysis.

5.3Preclinicalsafetydata

Preclinicaldatarevealnospecialhazardforhumansbasedonconventionalstudiesofgeneralpharmacology,

genotoxicityandcarcinogenicpotential.Thetoxicpotentialofthecombinationoflosartan/hydrochlorothiazidewas

evaluatedinchronictoxicitystudiesforuptosixmonthsdurationinratsanddogsafteroraladministration,andthe

changesobservedinthesestudieswiththecombinationweremainlyproducedbythelosartancomponent.The

administrationofthelosartan/hydrochlorothiazidecombinationinducedadecreaseintheredbloodcellparameters

(erythrocytes,haemoglobin,haematocrit),ariseinurea-Nintheserum,adecreaseinheartweight(withouta

histologicalcorrelate)andgastrointestinalchanges(mucousmembranelesions,ulcers,erosions,haemorrhages).

Therewasnoevidenceofteratogenicityinratsorrabbitstreatedwiththelosartan/hydrochlorothiazidecombination.

Foetaltoxicityinrats,asevidencedbyaslightincreaseinsupernumeraryribsintheF

generation,wasobservedwhen

femalesweretreatedpriortoandthroughoutgestation.Asobservedinstudieswithlosartanalone,adversefoetaland

neonatalreactions,includingrenaltoxicityandfoetaldeath,occurredwhenpregnantratsweretreatedwiththe

losartan/hydrochlorothiazidecombinationduringlategestationand/orlactation

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Eachtabletcontainsthefollowinginactiveingredients:

Microcrystallinecellulose(E460),

Lactosemonohydrate,

Pregelatinizedmaizestarch,

Magnesiumstearate(E572),

Hydroxypropylcellulose(E463),

Hypromellose(E464).

Titaniumdioxide(E171)

Carnaubawax(E903).

8.48mg(0.216mEq)ofpotassium.

6.2Incompatibilities

Notapplicable.

6.3ShelfLife

Theshelf-lifeexpirydateofthisproductshallbethedateshownontheblisterandouterpackageoftheproductonthe

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 14

6.4Specialprecautionsforstorage

Donotstoreabove30°C.Storeintheoriginalpackageinordertoprotectfromlightandmoisture.

6.5Natureandcontentsofcontainer

Blisterpackcontaining28film-coatedtablets.Inanover-labelledoutercarton.

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

Nospecialrequirements

7PARALLELPRODUCTAUTHORISATIONHOLDER

IPSHealthcareLimited

SterlingHouse

501MiddletonRoad

Chadderton

Oldham

Lancashire

OL99LY

UnitedKingdom

8PARALLELPRODUCTAUTHORISATIONNUMBER

PPA1659/16/1

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:8thOctober2010

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/10/2010 CRN 2083923 page number: 15